Elsevier

The Lancet

Volume 312, Issue 8104, 30 December 1978, Pages 1323-1327
The Lancet

CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS

https://doi.org/10.1016/S0140-6736(78)91970-0Get rights and content

Abstract

Seven patients on dialysis with renal failure received transplants from mismatched cadaver donors and were treated with cyclosporin A (CyA), initially as the sole immunosuppressive agent. CyA was effective in inhibiting rejection but there was clear evidence of both nephrotoxicity and hepatotoxicity. A cyclophosphamide analogue was added to the CyA treatment in six of the patients. Five patients are out of hospital with functioning allografts, and two of these have received no steroids. One patient required an allograft nephrectomy because of pyelonephritis in the graft. Another died of systemic aspergillus and candida infection. Further careful study of this potentially valuable drug will be required before it can be recommended in clinical practice.

References (13)

  • R.Y. Calne et al.

    Lancet

    (1978)
  • C.J. Green et al.

    Lancet

    (1978)
  • R.L. Powles et al.

    Lancet

    (1978)
  • J.F. Borel et al.

    Ag. Actions

    (1976)
  • A.J. Kostakis et al.

    I.R.C.S. med. Sci.

    (1977)
  • R.Y. Calne et al.

    I.R.C.S. med. Sci.

    (1977)
There are more references available in the full text version of this article.

Cited by (853)

  • Kidney transplantation: The journey across a century

    2023, Medical Journal Armed Forces India
  • Glucocorticoids, Cyclosporine, Azathioprine, Chlorambucil, and Mycophenolate in Dogs and Cats: Clinical Uses, Pharmacology, and Side Effects

    2022, Veterinary Clinics of North America - Small Animal Practice
    Citation Excerpt :

    In patients with intolerable or life-threatening glucocorticoid side effects or those that lack any clinically significant response to steroids with 7 to 14 days are cases whereby alternative immunosuppressive drugs need consideration; continued high dose and long-duration steroids are unlikely to achieve a favorable clinical outcome. Clinical Uses in Dogs and Cats: The initial use of cyclosporine in human and veterinary medicine was in the management of transplant recipients,31,32 but cyclosporine uses continue to expand to include the treatment of inflammatory and immune-mediated diseases.33 Specifically in veterinary medicine, cyclosporine is considered first-line therapy for perianal fistulas34–38 keratoconjunctivitis sicca (KCS or dry eye),39 and in some patients with atopic dermatitis.40–42

View all citing articles on Scopus
View full text